ELAN Earnings Date: Nov 6, 2026 — Elanco Animal Health Incorporated
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is ELAN's next earnings date?
Elanco Animal Health Incorporated (ELAN) is scheduled to report Q3 2026 earnings on Friday, November 6, 2026 at 6:27 AM ET (before market open). The consensus estimate is EPS of $0.20 on revenue of $1.21B.
How did ELAN do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Elanco Animal Health Incorporated posted EPS of $0.34 versus the $0.27 estimate, a beat of 25.9%. Revenue was $1.37B against a $1.31B estimate. The stock's 1-day post-earnings move was +2.4%.
How much does ELAN stock move after earnings?
ELAN beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.1% (up or down) in the day after earnings.
About Elanco Animal Health Incorporated
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | 0.27 | 0.34 | +25.93% | $1.37B | ✅ Beat | +2.42% | -11.21% | -3.59% |
| 2026-05-06 | Q1 2026 | 0.34 | 0.40 | +17.65% | $1.37B | ✅ Beat | +13.88% | -6.79% | +7.48% |
| 2026-02-24 | Q4 2025 | 0.11 | 0.13 | +18.18% | $1.14B | ✅ Beat | +6.59% | +5.41% | +0.61% |
| 2025-11-05 | Q3 2025 | 0.13 | 0.19 | +46.15% | $1.14B | ✅ Beat | -4.00% | +1.60% | -2.27% |
| 2025-02-25 | Q4 2024 | 0.15 | 0.14 | -6.67% | $1.02B | ❌ Miss | -3.69% | +1.80% | -5.40% |
| 2024-11-07 | Q3 2024 | 0.12 | 0.13 | +8.33% | $1.03B | ✅ Beat | +12.75% | +10.34% | -2.80% |
| 2024-08-08 | Q2 2024 | 0.24 | 0.30 | +25.00% | $1.02B | ✅ Beat | +4.93% | +13.73% | +21.89% |
| 2024-05-08 | Q1 2024 | 0.27 | 0.34 | +25.93% | $1.21B | ✅ Beat | +24.93% | +26.26% | +35.13% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $2.00B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Pet Health | 35.9% | $718.0M | +11.7% | $1.02B | $635.0M | $643.0M | $533.0M |
| Farm Animal | 31.6% | $633.0M | +8.6% | $1.16B | $546.0M | $583.0M | $593.0M |
| Cattle | 15.6% | $313.0M | +16.8% | $510.0M | $272.0M | $268.0M | $289.0M |
| Poultry | 11.1% | $223.0M | +3.7% | $411.0M | $189.0M | $215.0M | $217.0M |
| Swine | 4.8% | $97.0M | -3.0% | $194.0M | $85.0M | $100.0M | $87.0M |
| Contract Manufacturing | 0.8% | $17.0M | +13.3% | $22.0M | $12.0M | $15.0M | $11.0M |
By region
Q2 FY26 · $1.37B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Non-US | 51.5% | $705.0M | +8.8% | $545.0M | $639.0M | $648.0M | $590.0M |
| UNITED STATES | 48.5% | $663.0M | +11.8% | $475.0M | $554.0M | $593.0M | $547.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.